Uterine Fibroids Clinical Trial
Official title:
Office Based Evaluation of Patients Presenting With Abnormal Uterine Bleeding and/or Uterine Fibroids With Concurrent Office Hysteroscopy and Endometrial Biopsy; Does the Order Matter?
This study will look at the optimal order in which to perform concurrent office hysteroscopy and endometrial biopsy in female patients who present for evaluation of abnormal uterine bleeding at a fibroid and endometriosis treatment center.
This will be a prospective single blinded randomized control trial to determine whether the
order of performance of office hysteroscopy (OH) and endometrial biopsy (EMB) during the same
office evaluation for abnormal uterine bleeding affects the patient's pain perception. We
also intend to investigate whether the order of the procedures affects the adequacy of the
endometrial sample, duration of the procedure, and optimal visualization of the uterine
cavity. We hypothesize that performing EMB prior to OH will result in higher patient pain
scores.
Included patients will be all consecutive female patients ages 18-70 presenting to the
University of South Florida Center for Endometriosis and Fibroid Treatment (CFERT) for
evaluation of abnormal uterine bleeding or uterine fibroids.
Patients will be randomly assigned to have either OH followed by EMB or EMB followed by OH as
part of their clinical assessment of AUB/uterine fibroid based on clinical indication. The
patients will be informed about the two indicated procedures by their clinical provider but
will be blinded to the order of performance. The healthcare provider/investigator will be
aware of the order in which the procedures are assigned and to be performed. Patients will be
consented to participate in the study prior to the procedure by the study team on the day the
indicated procedures are scheduled in CFERT. The healthcare provider performing the procedure
will open an unlabeled envelope, within which there will be a piece of paper indicating which
procedure is to be performed first. This will then be recorded in the study log. The study
log will include enrolled patients, assigned study number which will range from 001 to the
minimum number of patients required for the study as indicated by sample size calculation.
At the end of the procedures, patient will be asked to describe their pain perception based
on Visual analogue scale (VAS) from 0-10. The adequacy of the endometrial sample will be
determined from the pathology report. The duration of the entire procedures (min) will be
timed using a stopwatch from the time of insertion of the hysteroscope/Pipelle catheter in
the external cervical canal to removal of the instruments. A panoramic picture of the
endometrial cavity will be taken and will be given to a blinded independent reviewer to
determine the adequacy of visualization based on 3 point scoring system (fair, good and
excellent). Fair visualization will be defined as no tubal ostia visualized; good will be
defined as both tubal ostia identified but only able to visualize 180 degrees of panorama;
excellent visualization will be defined as visualizing bilateral tubal ostia and having a
clear image of the uterine cavity in 360 degrees of panorama.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01441635 -
Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids
|
Phase 2 | |
Completed |
NCT00958334 -
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
|
Phase 2 | |
Withdrawn |
NCT04567589 -
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada
|
||
Recruiting |
NCT05078307 -
Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids
|
N/A | |
Recruiting |
NCT02283502 -
Clinical Test of the MRgHIFU System on Uterine Fibroids
|
Phase 1 | |
Completed |
NCT01631903 -
Extension of Study ZPV-200
|
Phase 2 | |
Completed |
NCT01739621 -
Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200
|
Phase 2 | |
Withdrawn |
NCT00768742 -
Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study
|
N/A | |
Completed |
NCT00152256 -
A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids
|
Phase 3 | |
Not yet recruiting |
NCT03586947 -
Association Between Vitamin D and the Risk of Uterine Fibroids
|
N/A | |
Completed |
NCT02925494 -
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
|
Phase 3 | |
Not yet recruiting |
NCT06055114 -
Study on Vaginal Microecology and Cervical Local Immune Function in Patients With Uterine Fibroids of Childbearing Age
|
||
Terminated |
NCT05026502 -
A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
|
||
Withdrawn |
NCT04567095 -
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada
|
||
Withdrawn |
NCT03699176 -
Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
|
Phase 3 | |
Not yet recruiting |
NCT02884960 -
Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization
|
N/A | |
Completed |
NCT01452659 -
Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids
|
Phase 2 | |
Terminated |
NCT01555073 -
Preemptive Analgesia Following Uterine Artery Embolization
|
Phase 4 | |
Completed |
NCT01229826 -
Magnetic Resonance Elastography (MRE) of Uterine Fibroids
|
N/A | |
Terminated |
NCT00785356 -
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
|
Phase 3 |